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ERLIN2 promotes breast cancer cell survival
by modulating endoplasmic reticulum stress
pathways
Guohui Wang1,2,8†, Gang Liu1†, Xiaogang Wang1†, Seema Sethi3,6, Rouba Ali-Fehmi4, Judith Abrams3,7, Ze Zheng2,
Kezhong Zhang1,2,5*, Stephen Ethier1,9 and Zeng-Quan Yang1,3*
Abstract
Background: Amplification of the 8p11-12 region has been found in approximately 15% of human breast cancer
and is associated with poor prognosis. Previous genomic analysis has led us to identify the endoplasmic reticulum
(ER) lipid raft-associated 2 (ERLIN2) gene as one of the candidate oncogenes within the 8p11-12 amplicon in human
breast cancer, particularly in the luminal subtype. ERLIN2, an ER membrane protein, has recently been identified as
a novel mediator of ER-associated degradation. Yet, the biological roles of ERLIN2 and molecular mechanisms by
which ERLIN2 coordinates ER pathways in breast carcinogenesis remain unclear.
Methods: We established the MCF10A-ERLIN2 cell line, which stably over expresses ERLIN2 in human
nontransformed mammary epithelial cells (MCF10A) using the pLenti6/V5-ERLIN2 construct. ERLIN2 over expressing
cells and their respective parental cell lines were assayed for in vitro transforming phenotypes. Next, we knocked
down the ERLIN2 as well as the ER stress sensor IRE1α activity in the breast cancer cell lines to characterize the
biological roles and molecular basis of the ERLIN2 in carcinogenesis. Finally, immunohistochemical staining was
performed to detect ERLIN2 expression in normal and cancerous human breast tissues
Results: We found that amplification of the ERLIN2 gene and over expression of the ERLIN2 protein occurs in both
luminal and Her2 subtypes of breast cancer. Gain- and loss-of-function approaches demonstrated that ERLIN2 is a
novel oncogenic factor associated with the ER stress response pathway. The IRE1α/XBP1 axis in the ER stress
pathway modulated expression of ERLIN2 protein levels in breast cancer cells. We also showed that over expression
of ERLIN2 facilitated the adaptation of breast epithelial cells to ER stress by supporting cell growth and protecting
the cells from ER stress-induced cell death.
Conclusions: ERLIN2 may confer a selective growth advantage for breast cancer cells by facilitating a
cytoprotective response to various cellular stresses associated with oncogenesis. The information provided here
sheds new light on the mechanism of breast cancer malignancy
Keywords: Gene amplification, Breast cancer, Endoplasmic reticulum, ERLIN2
Background
Breast cancer cells contain a large number of genetic
alterations that act in concert to create the malignant
phenotype. For example, the up-regulation of oncogenes,
such as Her2, c-MYC and CCND1, directly contributes
to the uncontrolled proliferation of breast cancer cells.
For cancer cells to survive, they must acquire the ability to
tolerate a series of oncogenesis-associated cellular stres-
sors, which include DNA damage, proteotoxic-, mitotic-,
metabolic-, and oxidative-stress [1,2]. However, very little
is currently known about the genomic basis and molecular
mechanisms that allow breast cancer cells to tolerate and
adapt to these stresses. Amplification of 8p11-12 occurs in
approximately 15% of human breast cancer (HBC). This
region of amplification is significantly associated with
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disease-specific survival and distant recurrence in breast
cancer patients [3-6]. Previous work in our laboratory, to-
gether with others, have identified the endoplasmic
reticulum (ER) lipid raft-associated 2 (ERLIN2, also known
as SPFH2, C8ORF2) gene as one of several candidate
oncogenes within the 8p11-12 amplicon, based on statis-
tical analysis of copy number increase and over expression
[3,4,7]. Yet, the biological roles of ERLIN2 and molecular
mechanisms by which ERLIN2 coordinates ER pathways
in breast carcinogenesis remain unclear.
The ER is a cellular organelle primarily responsible for
protein folding, lipid and sterol biosynthesis, and cal-
cium storage. Physiological processes that increase pro-
tein folding demand or stimuli that disrupt the ER
protein folding process can create an imbalance between
ER protein folding load and capacity. This imbalance
leads to the accumulation of unfolded or misfolded pro-
teins in the ER: a condition referred to as “ER stress”
[8,9]. The ER has evolved highly specific signaling path-
ways, collectively termed the “unfolded protein re-
sponse” (UPR), to ensure protein folding fidelity and to
protect the cell from ER stress. Upon activation of UPR,
inositol-requiring protein 1 (IRE1α), the conserved ER
stress sensor from yeasts to mammals, mediates splicing
of the mRNA encoding X-box binding protein 1 (XBP1).
XBP1 serves as a potent UPR trans-activator that helps
protein refolding, transportation, and degradation in
order to bolster ER capacity and facilitate cell adaptation
to stress [8]. However, if UPR fails to restore ER homeo-
stasis, ER stress-associated apoptosis will occur [10]. As
part of the UPR program, ER-associated degradation
(ERAD) targets aberrantly folded proteins in the ER. In
addition to this “quality control” function, ERAD also
accounts for the degradation of several metabolically-
regulated ER proteins [11].
Recent studies provide evidence that UPR and ERAD
components are highly expressed in various tumors, in-
cluding human breast cancer [12-21]. During tumor de-
velopment and progression, increased amounts of
misfolded proteins caused by gene mutations, hypoxia,
nutrient starvation, and high-levels of reactive oxygen
species lead to ER stress [22,23]. The activation of UPR
and ERAD induces an adaptive response in which the
tumor cell attempts to overcome ER stress to facilitate
cytoprotection. In this study, we demonstrated that amp-
lification and the resultant over expression of ERLIN2
occurred in both luminal and Her2 subtypes of breast
cancer. We also found that the UPR pathway, through
the IRE1α/XBP1 axis, modulated the high-level expres-
sion of ERLIN2 protein. Furthermore, ERLIN2 had the
ability to protect breast cancer cells from ER stress-
induced cell death. Thus, ERLIN2 is a novel mediator of
ER stress response and thus amplification and over ex-
pression of ERLIN2 may facilitate the adaptation of
breast cancer cells to the various cellular stresses asso-
ciated with oncogenesis.
Materials and methods
Cell lines and cell culture conditions
The culture conditions of of SUM breast cancer cells
and the immortalized non-tumorigenic MCF10A cells
are described in the Additional file 1: Materials and
Methods.
Genomic array CGH
Genomic array CGH experiments were performed using
the Agilent 44 K human genome CGH microarray chip
(Agilent Technologies, Palo Alto, CA). Agilent's CGH
Analytics software was used to calculate various meas-
urement parameters, including log2 ratio of total inte-
grated Cy-5 and Cy-3 intensities for each probe.
Semiquantitative RT-PCR reactions
Total RNA was prepared from human breast cancer cell
lines and the MCF10A cell line by standard methods
[3,24]. For RT-PCR reactions, RNA was converted into
cDNA via a reverse transcription reaction using random
hexamer primers. Primers were ordered from Invitrogen
(Carlsbad, CA). A GAPDH primer set was used as a
control. Semiquantitative RT-PCR was done using the
iQSYBR Green Supermix (Bio-Rad, Hercules, CA).
Lentivirus construction and transduction of cells
The lentiviral expression construct containing the
ERLIN2 gene (pLenti-ERLIN2), was established as previ-
ously described [3]. The lentivirus for pLenti-ERLIN2
was generated and used to infect the immortalized, non-
transformed mammary epithelial MCF10A cells. Control
infections with pLenti-LacZ virus were performed in
parallel with the pLenti-ERLIN2 infections. Selection
began 48 h after infection in growth medium with
10 μg/mL blasticidin in the absence of either insulin or
epidermal growth factor (EGF). Upon confluence,
selected cells were passaged and serially cultured.
Three-dimensional morphogenesis assays in matrigel
For three-dimensional morphogenesis assays in Matrigel,
cells grown in monolayer culture were detached by tryp-
sin/EDTA treatment and seeded in Matrigel (BD Bios-
ciences, San Jose, CA) precoated 8-well chamber slides.
The appropriate volume of medium was added and cells
were maintained in culture for 10–18 days. Phase-
contrast images and immunostaining images were taken
using bright-field and confocal microscopy.
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Lentivirus-mediated shRNA knockdown of gene
expression
We knocked down the expression of the human ERLIN2
gene in breast cancer cell lines and in the MCF10A cell
line using the Expression Arrest GIPZ lentiviral shRNA-
mir system (OpenBiosystems, Huntsville, AL). Lentivirus
was produced by transfecting 293FT cells with the com-
bination of the lentiviral expression plasmid DNA and
Trans-Lentiviral packaging mix (OpenBiosystems.
Huntsville, AL). For cell infection, viral supernatants
were supplemented with 6 μg/mL polybrene and incu-
bated with cells for 24 hours. Cells expressing shRNA
were selected with puromycin for 2–3 weeks for func-
tional studies (cell proliferation and colony formation
assays) and for 4 to 10 days after infection for RNA
extraction.
Recombinant adenoviral or retrovirus infection
Adenoviruse vectors for expressing flag-tagged IRE1α
isoforms, including wild type IRE1α (Ad-IRE1α WT),
IRE1α kinase mutant (Ad-IRE1α K599A), and IRE1α
RNase mutant (Ad-IRE1α K907A), were kindly provided
by Dr. Yong Liu (Institute for Nutritional Sciences,
Shanghai, China) and amplified using the AdEasy System
(Stratagene) [25,26]. Retrovirus expressing spliced XBP1
was kindly provided by Dr. Lauri Glimcher (Harvard
University) [27]. For infection of cells with adenovirus
and retrovirus, cells were seeded in six-well plates. After
24 h, cells were infected with adenovirus expressing wild
type IRE1α (Ad-IRE1α WT), IRE1α kinase mutant (Ad-
IRE1α K599A), IRE1α RNase mutant (Ad-IRE1α
K907A), and retrovirus expressing spliced XBP1 as
described previously [28,29].
Tissue array and immunohistochemistry (IHC) staining
Human breast cancer tissue array was obtained from
Nuclea Biotechnologies (Pittsfield, MA). Immunohisto-
chemistry was performed on tumor tissue sections using
the standard laboratory protocols [30]. Briefly, after
deparaffinizing and hydrating with phosphate-buffered
saline (PBS) buffer (pH 7.4), the sections were pretreated
with hydrogen peroxide (3%) for 10 minutes to remove
endogenous peroxidase, followed by antigen retrieval via
steam bath for 20 minutes in EDTA. A primary antibody
was applied, followed by washing and incubation with
the biotinylated secondary antibody for 30 minutes at
room temperature. Detection was performed with diami-
nobenzidine (DAB) and counterstaining with Mayer
hematoxylin followed by dehydration and mounting.
Immunostained slides were blindly evaluated under a
transmission light microscope. Areas of highest staining
density were identified for evaluating the expression in
tumors.
Results
ERLIN2 is amplified and over expressed in human breast
cancer cells
Recently, we used quantitative genomic PCR and array
comparative genomic hybridization (CGH) to profile copy
number alterations in 10 human breast cancer cell lines
and 90 primary human breast cancers [3,6,31]. Analysis of
our array CGH data showed that ERLIN2 gene was com-
monly amplified in 30% of the cell lines tested, as well as
in 7.8% of breast cancer specimens tested (Figure 1a). Pre-
viously, we and several other laboratories have demon-
strated that the 8p11-12 amplicon occurs mainly in the
luminal subtype of breast cancer cells, such as the SUM-
44 and SUM-52 cell lines. However, SUM-225 is a Her2-
amplified HBC cell line [31,32]. We also found two pri-
mary tumors, 10173 and 9895, which have Her2 gene
amplifications in addition to the amplification of the
ERLIN2 gene (Figure 1a). To obtain further support for a
potential involvement of the ERLIN2 region in breast can-
cer, we searched the published database of the Affymetrix
250 K array CGH [33]. We found that 42 of the 243 HBC
lines and primary samples in the array exhibited amplifica-
tion of the ERLIN2 region. Interestingly, eight of the
ERLIN2-amplified samples showed co-amplification of the
Her2 gene (Additional file 1: Figure S1). Next, we mea-
sured ERLIN2 protein levels in ten breast cancer cell lines
by Western blot analysis. In correlation with ERLIN2 gene
amplification, ERLIN2 protein levels in SUM-44, SUM-52,
and SUM-225 cells were dramatically greater than the
levels in breast cancer cell lines without ERLIN2 gene
amplification (Figure 1b). The presence of the ERLIN2
amplification in both luminal and Her2 subtypes of breast
cancer prompted us to further investigate the role of the
ERLIN2 gene in breast cancer progression.
ERLIN2 plays a functional role in breast cancer cells
Next, we addressed whether ERLIN2 possess transform-
ing properties. We transduced the immortalized, non-
transformed mammary epithelial cell line, MCF10A,
with lentivirus expressing ERLIN2 or control LacZ.
Semi-quantitative RT-PCR (qRT-PCR), Western blot and
immunofluorescence staining confirmed the over ex-
pression of ERLIN2 protein in MCF10A-ERLIN2 cells
(Figure 2a and Additional file 1: Figure S2). The infected
MCF10A cells were then subjected to analyses for
growth rates, growth factor-independent proliferation,
anchorage-independent growth, and three-dimensional
morphogenesis assays. Growth curves and colony forma-
tion assays in MCF10A cells showed that forced expres-
sion of ERLIN2 resulted in growth factor-independent
proliferation in insulin-like growth factor-deficient
media. To further examine the effects of ERLIN2 in a
context that more closely resembles in vivo mammary
architecture, we assessed the consequences of ERLIN2
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over expression on three-dimensional morphogenesis in
Matrigel. Although MCF10A cells formed polarized,
growth-arrested acinar structures with hollow lumens
similar to the glandular architecture in vivo, MCF10A-
ERLIN2 cells formed abnormal acini at a high frequency
that was grossly disorganized, and contained filled
lumens (Figure 2b).
To further explore the pathophysiological function of
ERLIN2 over expression, we stably silenced the ERLIN2
gene in SUM-44 and SUM-225 breast cancer cells using
the lentiviral-based shRNA system. To perform RNAi
knockdown experiments, we utilized pGIPZ-ERLIN2
shRNA expression constructs in which TurboGFP and
shRNA were part of a bicistronic transcript allowing for
the visual marking of the shRNA-expressing stable cells.
qRT-PCR and Western blot analysis indicated a marked
reduction in expression levels of ERLIN2 mRNA and
protein in the stable ERLIN2-shRNA-transduced SUM-44
and SUM-225 cell lines as compared with the control cell
lines infected with a non-silencing shRNA lentiviral con-
trol (Figure 3a). Among the two targeted vectors used,
ERLIN2-shRNA vector #1 produced a more striking
knockdown effect: infected SUM-225 cells had a nearly
complete loss of ERLIN2 protein expression (Figure 3a).
We did not detect any change in ERLIN1 mRNA and pro-
tein levels in ERLIN2-shRNA knockdown cells, thus ruling
out the possiblity of off-target effects by ERLIN2-shRNAs
(Data not shown). Cell growth and proliferation analyses
showed that knockdown of ERLIN2 slowed the prolifera-
tion rate of SUM-44 and SUM-225 cells, but had only a
minor effect on SUM-102 and MCF10A cells, which lack
ERLIN2 amplification (Figure 3b). Importantly, knock-
down of ERLIN2 in SUM-44 and SUM-225 cells also sup-
pressed anchorage-independent growth in soft agar, one of
Figure 1 (a) Genomic copy number profiles of the ERLIN2 region analyzed on the Agilent oligonucleotide array CGH in 3 SUM breast
cancer cell lines and 7 primary breast cancer specimens. Tumors are displayed vertically and array probes are displayed horizontally by
genome position. Log2 ratio in a single sample is relative to normal female DNA and is depicted according to the color scale (bottom). Red
indicates relative copy number gain, whereas green indicates relative copy number loss. (b) ERLIN2 protein levels were analyzed by Western blot
in ten breast cancer cell lines with or without ERLIN2 amplification.
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the hallmark characteristics of aggressive cancer cells.
(Figure 3c). Taken together, results from over expression
and knockdown experiments suggested ERLIN2 plays a
role in cell proliferation and maintenance of transforming
phenotypes in breast cancer cells with the 8p11-12
amplification.
Expression of ERLIN2 is regulated by the ER pathway
through IRE1α/XBP1
Recent studies have identified ERLIN2 both as a novel
component of lipid raft domains in the ER membrane
and as a substrate recognition factor during ERAD of
activated inositol triphosphate receptors (IP3R) as well
as other substrates [34-36]. IRE1α is the primary ER
stress sensor implicated in the regulation of the ERAD
pathway [37]. Under ER stress, IRE1α undergoes auto-
phosphorylation to activate its RNase activity, which
triggers one of the UPR cascades through splicing Xbp1
mRNA [8]. Previous work has demonstrated that breast
cancer cells over express XBP1 [38,39], while we
observed that SUM-44, SUM-52 and SUM-225 cell lines
over expressed total and activated XBP1 (Additional file
1: Figure S3 Additional file 2: Table S1). To evaluate the
possibility of an association between ERLIN2 expression
and the IRE1α-mediated UPR pathway in HBC, we
inhibited IRE1α RNase or kinase activity in breast cancer
cells. To accomplish this, we used adenoviral-based ex-
pression system to introduce the previously character-
ized IRE1 kinase dominant-negative mutant (IRE1
K599A) or the IRE1 RNase dominant-negative mutant
(IRE1 K907A) into breast cancer cells [26,40,41]. We
chose SUM-44 cells for this experiment because the
SUM-44 cells are very amenable to adenovirus-mediated
expression. The inhibition of the IRE1α RNase activity
significantly reduced protein levels of ERLIN2 in SUM-
44 cells (Figure 4a). In addition, forcible expression of
wild-type IRE1α or spliced XBP1 in MCF10A cells
resulted in increased expression levels of endogenous
ERLIN2 protein (Figure 4b and c). However, quantitative
real-time RT-PCR analysis showed that over expression
of IRE1α or spliced XBP1 did not increase expression of
the ERLIN2 mRNA (Data not shown). Next, we asked
whether ERLIN2 expression was induced by stress indu-
cers in normal mammary epithelial cells. Our group rou-
tinely cultures MCF10A cells in serum-free, growth
factor-supplemented media. Oncogenesis-associated
conditions, such as nutrient or growth factor depletion,
can cause pathophysiologic ER stress [22,23]. When
MCF10A cells were cultured in media lacking insulin or
EGF, expression levels of endogenous ERLIN2 protein in
MCF10A were increased as compared with levels in cells
cultured in normal media (Figure 4d). Our observations
Figure 2 (a) Stable overexpressing ERLIN2 in MCF10A cells (MCF10A-ERLIN2) with the pLenti6/V5-ERLIN2 construct. Over expression of
ERLIN2 mRNA and protein in this cell line was confirmed with semi-quantitative RT-PCR (right panel) and western blot assays (left panel). (b)
Effects of ERLIN2 on mammary acinar morphogenesis. MCF10A-ERLIN2 and control cells were cultured on a bed of Matrigel. Representative
images show the structures with staining for actin with phalloidin conjugated to Alexa Fluor-568 (red), and DAPI as a marker of nuclei (blue).
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Figure 3 shRNA-mediated knockdown of ERLIN2 inhibits monolayer and anchorage-independent cell growth in breast cancer cells
with ERLIN2 amplification. (a) Knockdown of ERLIN2 expression in SUM-44 and SUM-225 cells with two different shRNAs was confirmed by
western blot. (b) In vitro growth rate of SUM-44 and SUM-225 cells with ERLIN2 shRNA treatment compared to cells with control shRNA
treatment. (c) Knockdown of ERLIN2 reduces colony formation in soft agar. SUM-44 and SUM-225 cells were tranfected with ERLIN2 shRNA#1 or
control shRNA. The colony numbers were counted 3 weeks later (P< 0.05).
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suggest that the ER stress pathway likely regulates
ERLIN2 protein expression through IRE1α-actived XBP1
in human breast epithelial cells.
ERLIN2 promotes breast cancer cell survival
Next, we tested if amplification and over expression of
ERLIN2 enhances the resistance to a variety of stressors
to promote cancer cell survival. Figure 5a shows the
IC50 values for the ER stress-inducing reagent Tunica-
mycin (Tm), in ten breast cancer cell lines as well as in
the nontransformed human mammary epithelial cell line
MCF10A. SUM-44 and SUM-225 cells, which have
ERLIN2 amplification, had significantly higher TM IC50
values than cell lines without ERLIN2 amplification
(P< 0.05). We obtained similar results with Thapsigargin
(Tg) treatment of SUM-225 cells (data not shown). Ex-
pression of the CCAAT/enhancer-binding protein (C/
EBP) homology protein (CHOP) is characteristic of the
ER stress–mediated apoptotic pathway. In response to
treatment with Tm or Tg, expression of CHOP dramat-
ically increased in control MCF10A cells (Figure 5b).
However, induction of CHOP by Tm and Tg treatment
was weaker or barely detectable in SUM-44 and SUM-
225 cells (Figure 5b). Next, to determine whether
suppressing ERLIN2 in breast cancer cells re-sensitize
them to ER-stress, we challenged stable ERLIN2-
knockdown SUM-44 and SUM-225 cells with Tm and
Tg for 72 hours and evaluated their viability using the
MTT assay. Knockdown of ERLIN2 resulted in increased
sensitivity to Tm or Tg -induced cell death (Figure 5c).
Our data suggested that over expression of ERLIN2 may
facilitate the adaptation of breast epithelial cells to ER
stress by supporting cell growth. Future investigations
are required to more precisely address the mechanism
by which ERLIN2 promotes breast cancer cell survival.
Expression of ERLIN2 in breast tissues: Carcinomas and
normal
We evaluated the expression of ERLIN2 in normal and
cancerous human breast tissues using immunohisyo-
chemistry (IHC) in breast cancer tissue arrays. We first
confirmed the specificity and sensitivity of the ERLIN2
antibody for visualizing ERLIN2 expression in formalin-
fixed, paraffin-embedded breast cancer cell lines. Con-
sistent with the immunoblotting data, SUM-225 cells
displayed significantly higher levels of positive staining
as compared with the MCF10A control cells (Additional
file 1: Figure S4). The tissue array included 34 breast
Figure 4 (a) The knockdown of the IRE1α RNase activity (K907A) reduced levels of ERLIN2 protein in SUM-44 cells. Forced expression of
wild-type IRE1α (b) and its substrate, spliced XBP1 (c), leads to increased expression of ERLIN2 at protein level in MCF10A cells. (d) ERLIN2
expression in MCF10A cells was analyzed by western blot after culture 48 hours in insulin- or EGF-depleted media, compared to that in normal
culture media.
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carcinomas and 17 normal breast tissue, which included
14 cases of adjacent normal counterparts. ERLIN2 ex-
pression was scored based on the staining intensity: 0
(negative), 1 + (weak), 2 + (low); 3+ (moderate) or
4 + (strong). In breast carcinomas samples, 11 (32.4%)
stained ERLIN2 strongly and 13 (38.2%) moderately
Figure 5 (a) IC50 values for the ER stress-inducing reagent Tm, in ten breast cancer cell lines as well as in the MCF10A cells (b) The
expression level of CHOP in SUM-225, SUM-44 breast cancer cells and MCF10A control cells was analyzed with Western blot after Tm
(500 ng) or Tg (400 nM) treatment. (c) Cell viability of ERLIN2 knockdown and control SUM-225 cells was measured with MTT assays after
exposure to different concentrations of the Tm or Tg for 72 hours.
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(Figure 5, Additional file 1: Figure S5 Additional file 2:
Table S2). In contrast, no strong or moderate staining
was observed in the 17 normal breast tissues. The stain-
ing intensities of ERLIN2 were significantly higher in
tumor cells than in normal tissue cells (P = 0.001).
Discussion
The 8p11-12 amplicon in HBC has been the subject of a
number of studies using high-resolution genomic analysis
of copy number and gene expression [3-6,42,43]. We pre-
viously found that the 8p11-12 amplicon has a highly
complex genomic structure and that the size of the ampli-
con in three HBC lines, SUM-44, SUM-52 and SUM-225,
is highly variable [6,31]. Moreover, the sub-amplicon of
8p11-12 that carries the ERLIN2 gene amplification was
more frequently identified in HBCs [4,7]. Previous studies
have demonstrated that the 8p11-12 amplicon occurs
mainly in the luminal subset of breast cancer cells, such as
SUM-44 cells, a subset that also expresses the estrogen re-
ceptor [3,4,7,44-46]. Here we report that the co-
amplification of the ERLIN2 region occurred in a subset of
HER2-amplified breast cancer cells, including SUM-225
cells. Our recent studies with Her2 model cells demon-
strated that over expression of Her2 alone is not sufficient
to induce full transformation in vitro and is not tumori-
genic in vivo [47]. In contrast, Her2-amplified SUM225
breast cancer cells are fully transformed in vitro and
tumorgic in vivo [48]. In this study, in vitro transforming
and shRNA assays provided evidence that ERLIN2 is the
most likely non- classical oncogene within this 8p11-12
minimal common amplified region. Our results suggest
that the ERLIN2 plays a role in cell proliferation and main-
tenance of transforming phenotypes in breast cancer cells
with the 8p11-12 amplification.
ERLIN2 belongs to a larger family of proteins that share
an evolutionarily conserved stomatin/prohibitin/flotillin/
HflK/C (SPFH) domain. SPFH-containing proteins localize
to different membranes, but have common characteristics.
For example, N-terminal sequences are required for sub-
cellular localization and membrane attachment, while the
coiled-coil motifs located at the C-terminal side of SPFH
domain mediate the assembly of high-molecular-weight
complexes [49]. ERLIN2 and its homologue ERLIN1 were
originally identified as components of lipid rafts that
localize to the ER [36]. More recently, ERLIN2 has been
recognized as a novel mediator of ERAD [34-36,50].
ERLIN2 binds to activated IP3Rs and other ERAD sub-
strates, leading to polyubiquitination and subsequent deg-
radation of these substrates [34,35].
Of particular interest in this study, we found that the
UPR pathway modulated ERLIN2 protein expression in
breast cancer cells through the IRE1α/XBP1 axis. Forced
expression of IRE1α, or spliced XBP1, the target of
IRE1α under ER stress, up-regulated expression of the
ERLIN2 protein, while knockdown of IRE1α RNase ac-
tivity decreased ERLIN2 expression in the ERLIN2-amp-
lified breast cancer cells. These gain- and loss-of-
function studies provided support that the IRE1α/XBP1-
mediated UPR pathway in HBC regulated production of
ERLIN2. Importantly, our study also showed that the de-
pletion of nutrient and growth signals, a condition that
is associated with oncogenesis and ER stress, can in-
crease ERLIN2 production in breast epithelial cells.
However, over expression of IRE1α or spliced XBP1 did
not increase expression of the ERLIN2 mRNA level, sug-
gesting regulation at the post-transcription level. In the
present study, we also showed that expression of pri-
mary breast cancer cells significantly up regulated
ERLIN2 protein expression as compared with normal
breast cells. As we had described earlier, amplification of
the ERLIN2 gene, as part of the 8p11-12 amplicon,
occurs in approximately 15% of human breast cancer. It
is reported that XBP1 is over expressed in aggressive
breast cancer and associated with cancer cell survival
and therapy resistance [51]. In the ten SUM breast can-
cer cell lines we investigated, three lines have both
ERLIN2 gene amplification and up-regulation of acti-
vated XBP1, resulting in dramatically high-level expres-
sion of ERLIN2 protein. In contrast, two lines with up-
regulation of the XBP1, but no ERLIN2 gene amplifica-
tion, had moderately high-expression of the ERLIN2
protein. Taken together, our results raise an intriguing
notion that the breast cancer cells may utilize gene amp-
lification and the UPR pathway to regulate ERLIN2 pro-
tein over-production under oncogenic stress conditions.
In response to ER stress, cells activate UPR to repro-
gram gene transcription and translation. Depending on
the type and/or degree of the stress, cells can differen-
tially activate the UPR pathways in order to make sur-
vival or death decisions [52]. The literature indicates
that the UPR branch, through IRE1α/XBP1, plays a crit-
ical role in cell adaptation to ER stress by increasing
protein refolding and degradation of misfolded proteins,
and by bolstering the protein-folding capacity and
Figure 6 Immunohistotochemical staining of ERLIN2 protein on
a representative HBC sample and a normal control.
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secretion potential of the ER [20,52,53]. Cancer cells
may adapt to the cellular stress and evade stress-induced
apoptotic pathways by differentially activating the UPR
branches. Indeed, tumor microenvironment has been
characterized by a ‘baseline’ level of ER stress response
that promotes tumor development and metastasis [20].
Conclusions
In the present study, we show that over expression of
ERLIN2 may facilitate the adaptation of breast epithelial
cells to ER stress by supporting cell growth and protect-
ing the cells from ER stress-induced apoptosis. These
results suggest that ERLIN2 confers a selective growth
advantage for breast cancer cells by facilitating a cyto-
protective response to various cellular stresses associated
with oncogenesis. The information provided here sheds
new light the mechanism of breast cancer malignancy.
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